Guidant Passes On Impulse Buy, Refines Business Grouping For Better Focus
This article was originally published in The Gray Sheet
Executive Summary
Guidant will pass on an option to acquire exclusive rights to certain Impulse Dynamics experimental heart failure technologies in favor of in-house cardiac resynchronization therapies currently under clinical evaluation in the U.S. and Europe for heart failure.